Modernizing the clinical risk score to more accurately predict survival following resection of colorectal liver metastases
To date, the National Cancer Institute, NIH estimates 140,250 new colorectal cancer cases for 2018 (1). Out of this population, 20% will present with synchronous metastatic disease and up to 50% will develop metastatic disease. Moreover, in those who develop metastases, the liver is involved 80% of the time. Although historical controls found rare survivors to be noted at 3 years and a median overall survival of 6–12 months in untreated but potentially resectable patients; modern data has found that a multidisciplinary approach incorporating surgical extirpation may allow for up to 55% and 24% actual 5- and 10-year survivors (2,3).